16 results about "Viral structural protein" patented technology

The invention provides a recombinant oncolytic virus for treating solid tumors with rare and rare gene mutations, which is an OAV treatment platform subjected to triple virus structural protein gene modification and triple adenovirus serotype chimerism, and is named as NeoViron. NeoViron can directly deliver tumor neoantigens to a plurality of solid tumors, especially tumors with rare mutations, and a new general strategy is provided for treating a plurality of intractable tumors.

The invention provides a PDCoV virus mRNA (messenger Ribonucleic Acid) vaccine capable of self-cleaving and expressing a plurality of virus structural proteins and a preparation method of the PDCoV virus mRNA vaccine, and the vaccine comprises mRNA for expressing S, M and N proteins of a PDCoV virus and LNP for encapsulating the mRNA, and the LNP is marked as SMN-mRNA-LNP. The invention provides a PDCoV mRNA vaccine strategy based on combination of S, M and N for the first time, the S, M and N structural proteins of the PDCoV are connected by using a self-cleavage peptide P2A, the S protein is subjected to double proline mutation, so that a single mRNA can express multiple PDCoV antigens, and a multi-level defense system is constructed by using the neutralizing antibody induction capability of the S protein, the immune regulation function of the M protein and the cellular immune activation characteristic of the N protein. Through evaluation of immunogenicity, antibody level and challenge protection effect of the vaccine in mice, suckling piglets and pregnant sows, a new idea is provided for development of broad-spectrum and efficient PDCoV vaccines, and a practical basis is provided for research and development of coronavirus multi-antigen mRNA vaccines.

The application provides a PDCoV virus mRNA vaccine which can be self-cleaved and expresses multiple virus structure proteins and a preparation method thereof, the vaccine comprises mRNA for expressing PDCoV virus S, M and N proteins, and LNP for encapsulating the mRNA, denoted as SMN-mRNA-LNP. The application firstly proposes a PDCoV mRNA vaccine strategy based on S, M and N combination, connects three structure proteins of PDCoV S, M and N by using a self-cleaving peptide P2A, mutates the S protein with double proline, enables a single mRNA to express multiple PDCoV antigens, and utilizes the neutralizing antibody induction ability of the S protein, the immune regulation function of the M protein and the cell immune activation characteristics of the N protein to construct a multi-level defense system. Through evaluation of immunogenicity, antibody level and challenge protection effect of the vaccine in mice, suckling piglets and pregnant sows, a new idea for developing a broad-spectrum and high-efficiency PDCoV vaccine is provided, and practical basis for research and development of a coronavirus multi-antigen mRNA vaccine is provided.

Disclosed herein are vaccine constructs for producing a virus-like particle (VLP) capable of raising an immune response to an immunogen, and uses thereof, wherein the constructs comprise nucleic acid sequences encoding an immunogen and a polyprotein, wherein the polyprotein comprises two or more viral structural proteins, wherein at least two of the two or more viral structural proteins are separated by a signal peptidase sequence such that, when the polyprotein is expressed in a host cell, the signal peptidase sequence undergoes host cell peptidase-dependent cleavage to liberate the two or more viral structural proteins, thereby allowing the liberated structural proteins to self-assemble into a VLP carrying the immunogen.

This invention provides the application of apatinib in the preparation of antiviral drugs, specifically involving the application of the anticancer drug apatinib in inhibiting the replication of Hantanensis virus (HTNV) and Chikungunya virus (CHIKV). Apatinib can significantly inhibit HTNV replication and reduce viral titers at the cellular level. Experiments have shown that after treatment with apatinib, the expression levels of viral structural proteins, the nucleic acid levels of HTNV, and the viral titers in the cell culture supernatant were significantly reduced in HTNV-infected A549 cells, while the drug exhibited low cytotoxicity. Furthermore, apatinib can also inhibit CHIKV replication. This invention provides a novel anti-HTNV candidate drug and offers insights for the rapid development of antiviral drugs.

The present invention is in the field of Nipah virus (NiV) structural protein. Particularly, the invention provides structure based stabilized Nipah virus (NiV) structural protein designing and uses thereof.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncolytic defective virus compositions and methods of in vivo synthesis thereof. The composition includes a first nucleic acid construct encoding a self-amplifying mRNA (sa-mRNA) encoding at least one gene of interest (GOI) or a plurality of GOIs, a second nucleic acid construct encoding an mRNA encoding at least one virus structural protein, and at least one payload delivery system.

The invention belongs to the field of gene engineering, and particularly relates to application of chikungunya virus structural protein in improvement of pseudovirus stability, a construction method of the chikungunya virus structural protein and vaccines, antibody evaluation and in-vivo gene therapy products. The method comprises the following steps: constructing a human codon optimized Asian strain CHIKV-E3 + E2 + 6K + E1 structural protein eukaryotic vector, and designing two types of binder expression plasmids of targeted T cells; the vector, a psPAX2 helper plasmid and a lentivirus target vector containing an SFFV promoter and a ZsGreen reporter gene (or a CAR therapeutic gene) are co-transformed into a 293T cell, and the lentivirus is prepared through culture, filtration and centrifugation. The lentivirus can efficiently infect Jurkat cells and activate human T cells, obviously reduces the infection efficiency on 293T cells so as to reduce the off-target effect, has excellent stability in human serum, and provides a safe and efficient gene delivery tool for in-vivo CAR-T therapy.

The invention relates to the technical field of biology, in particular to a porcine reproductive and respiratory syndrome virus subunit vaccine. Through bioinformatics analysis and experimental verification, the antigen protein with excellent immunogenicity is obtained through screening, and the amino acid sequence of the antigen protein is shown as SEQ ID NO: 1. The subunit vaccine constructed on the basis of the protein can effectively induce mice to generate high-level neutralizing antibodies, the effect of the subunit vaccine is remarkably better than that of commercial control vaccines, the mice can be stimulated to generate strong humoral immunity and cellular immunity at the same time, and the induced immune response type is mainly Th2 type. Further research shows that the antigen protein and the virus structural protein E + M are combined for immunization, and the immune effect of the structural protein can be remarkably enhanced. The subunit vaccine developed by the invention provides a new thought for research and development of novel vaccines for resisting PRRSV and other viral diseases.

The invention belongs to the technical field of veterinary biological products, and particularly relates to a CATHAY topological truncated foot-and-mouth disease virus-like particle antigen and application thereof. Compared with the precursor protein P1 of the wild type foot-and-mouth disease virus structural protein, the precursor protein P1 of the CATHAY topological truncated foot-and-mouth disease virus structural protein has the advantage that 10-40 amino acids are truncated at the N end. While the relatively strong capability of inducing an organism to generate an antibody of the full-length wild capsid protein is reserved, the protein has the characteristics of high expression quantity, easiness in purification, high uniformity, high stability and the like.

The present disclosure provides a virus like particle comprising a viral structural protein and a galectin epitope peptide, and a composition or vaccine comprising thereof, its use in a medicine, particularly in an immunotherapy.

The invention belongs to the technical field of veterinary biological products, and particularly relates to an O-type truncated foot-and-mouth disease virus-like particle antigen and application thereof. Compared with a wild type foot-and-mouth disease virus structural protein precursor protein P1, the O-type truncated foot-and-mouth disease virus structural protein precursor protein P1 has the advantage that 10-40 amino acids are truncated at the N end of the O-type truncated foot-and-mouth disease virus structural protein precursor protein P1. While the relatively strong capability of inducing an organism to generate an antibody of the full-length wild capsid protein is reserved, the protein has the characteristics of high expression quantity, easiness in purification, high uniformity, high stability and the like.

The invention belongs to the technical field of veterinary biological products, and particularly relates to an A-type truncated foot-and-mouth disease virus-like particle antigen and application thereof. Compared with a wild type foot-and-mouth disease virus structural protein precursor protein P1, the N end of the A type truncated foot-and-mouth disease virus structural protein precursor protein P1 is truncated by 10-40 amino acids. While the relatively strong capability of inducing an organism to generate an antibody of the full-length wild capsid protein is reserved, the protein has the characteristics of high expression quantity, easiness in purification, high uniformity, high stability and the like.

This specification provides a viral particle comprising a heterologous viral structural protein, a targeting moiety, and at least one nucleic acid molecule encoding a gene editing system, a composition containing the same, and a method of using the same.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncolytic defective virus compositions and methods of in vivo synthesis thereof. The composition includes a first nucleic acid construct encoding a self-amplifying mRNA (sa-mRNA) encoding at least one gene of interest (GOI) or a plurality of GOIs, a second nucleic acid construct encoding an mRNA encoding at least one virus structural protein, and at least one payload delivery system.

Provided herein are viral particles comprising a heterologous viral structural protein, a targeting moiety, and at least one nucleic acid molecule encoding a gene editing system, compositions comprising these viral particles, and methods of using these viral particles.